Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
Updated results from the KEYNOTE-365 trial indicate that combining pembrolizumab with chemotherapy improves survival outcomes for patients with metastatic neuroendocrine prostate cancer compared to chemotherapy alone. While not yet FDA-approved for this specific use, the data suggests a potential new treatment pathway for this aggressive disease.
Why it matters
This research offers hope for improved clinical outcomes in a difficult-to-treat cancer where current standard-of-care options are limited.
At the 2026 European Society for Medical Oncology (ESMO) Congress, Gunhild von Amsberg, MD, professor of uro-oncology in the Department of Hematology and Oncology and the Martini-Klinik at University Medical Center Hamburg-Eppendorf in Germany, presented updated results from cohort I of the phase 1b/2 KEYNOTE-365 trial (NCT02861573).1 In patients with metastatic neuroendocrine prostate cancer (NEPC), adding pembrolizumab (Keytruda) to carboplatin and etoposide produced a higher objective response rate (ORR) and longer overall survival (OS) than chemotherapy alone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in